推荐产品
产品名称
Transglutaminase 2 Inhibitor, ZDON, A cell-permeable, peptide-based, irreversible inhibitor of transglutaminase 2 (TG2; IC₅₀ = 150 nM for recombinant TG2). Reacts with the active site cysteine of TG2.
质量水平
方案
≥98% (HPLC)
表单
powder
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
颜色
off-white
溶解性
DMSO: 50 mg/mL
运输
ambient
储存温度
−20°C
一般描述
A cell-permeable, peptide-based (Z- QVPL) irreversible inhibitor of transglutaminase 2 (TG2) (IC50 = 150 nM for recombinant TG2) that acts by reacting with the active site cysteine of TG2. Exhibits far less potency against TG1 and TG3. Shown to significantly increase PGC-1a and cytochrome c mRNA levels in Q7 and Q111 cells (~50 mM). Also shown to enhance cytochrome c promoter activity by 250% in Q111 cells. Exhibits protective effect in cells exposed to 3-nitropropionic acid and NMDA, however, it does not directly affect mitochondrial bioenergetics.
警告
Toxicity: Standard Handling (A)
重悬
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他说明
McConoughey, S. J., et al. 2010. EMBO Mol. Medicine.2, 349.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Min-Su Han et al.
Scientific reports, 10(1), 13228-13228 (2020-08-09)
Transglutaminase 2 (TG2), also known as tissue transglutaminase, is a calcium-dependent enzyme that has a variety of intracellular and extracellular substrates. TG2 not only increases in osteoarthritis (OA) tissue but also affects the progression of OA. However, it is still
Manuel Lisetto et al.
International journal of molecular sciences, 24(15) (2023-08-12)
Transglutaminase 2 (TG2) is a multifunctional protein widely distributed in various tissues and involved in many physiological and pathological processes. However, its actual role in biological processes is often controversial as TG2 shows different effects in these processes depending on
Anurag Rathore et al.
Scientific reports, 10(1), 5350-5350 (2020-03-27)
The major barrier to a HIV-1 cure is the persistence of latent genomes despite treatment with antiretrovirals. To investigate host factors which promote HIV-1 latency, we conducted a genome-wide functional knockout screen using CRISPR-Cas9 in a HIV-1 latency cell line
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门